피부경화증 진단 및 치료 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2023-2031년)

Scleroderma Diagnostics and Therapeutics Market - Scope of Report

TMR's report on the global scleroderma diagnostics and therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global scleroderma diagnostics and therapeutics market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global scleroderma diagnostics and therapeutics market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the scleroderma diagnostics and therapeutics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global scleroderma diagnostics and therapeutics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global scleroderma diagnostics and therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global scleroderma diagnostics and therapeutics market.

The report delves into the competitive landscape of the global scleroderma diagnostics and therapeutics market. Key players operating in the global scleroderma diagnostics and therapeutics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global scleroderma diagnostics and therapeutics market profiled in this report.

Key Questions Answered in Global scleroderma diagnostics and therapeutics Market Report:

• What is the sales/revenue generated by scleroderma diagnostics and therapeutics across all regions during the forecast period?
• What are the opportunities in the global scleroderma diagnostics and therapeutics market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Scleroderma Diagnostics and Therapeutics Market - Research Objectives and Research Approach

The comprehensive report on the global scleroderma diagnostics and therapeutics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global scleroderma diagnostics and therapeutics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global scleroderma diagnostics and therapeutics market.

Table of Contents

1. Executive Summary

• 1.1. Global Market Outlook
• 1.2. Demand Side Trends
• 1.3. Key Facts and Figures
• 1.4. Trends Impacting Market
• 1.5. TMR's Growth Opportunity Wheel

2. Market Overview

• 2.1. Market Segmentation
• 2.2. Market Trends
• 2.3. Market Dynamics
  • 2.3.1. Drivers
  • 2.3.2. Restraints
  • 2.3.3. Opportunities
• 2.4. Porter's Five Forces Analysis
• 2.5. Regulatory Analysis
• 2.6. Value Chain Analysis
  • 2.6.1. List of Raw Material Suppliers
  • 2.6.2. List of Key Manufacturers
  • 2.6.3. List of Suppliers/ Distributors
  • 2.6.4. List of Potential Customers
• 2.7. Product Specification Analysis
• 2.8. Overview of Manufacturing Process
• 2.9. Cost Structure Analysis

3. COVID-19 Impact Analysis

4. Price Trend Analysis

5. Global Scleroderma Diagnostics and Therapeutics Market Analysis and Forecast, by Drug Class, 2023-2031

• 5.1. Introduction and Definitions
• 5.2. Global Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
  • 5.2.1. Corticosteroids
  • 5.2.2. Immunosuppressive Agents
  • 5.2.3. Endothelin Receptor Agonists
  • 5.2.4. Calcium Channel Blockers
  • 5.2.5. PD5-Inhibitors
  • 5.2.6. Chelating Agents
  • 5.2.7. Prostacyclin Analogues
  • 5.2.8. H2 Blockers
  • 5.2.9. Proton Pump Inhibitors
  • 5.2.10. ACE Inhibitors
• 5.3. Global Scleroderma Diagnostics and Therapeutics Market Attractiveness, by Drug Class

6. Global Scleroderma Diagnostics and Therapeutics Market Analysis and Forecast, by Indication, 2023-2031

• 6.1. Introduction and Definitions
• 6.2. Global Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
  • 6.2.1. Systemic
  • 6.2.2. Localized
• 6.3. Global Scleroderma Diagnostics and Therapeutics Market Attractiveness, by Indication

7. Global Scleroderma Diagnostics and Therapeutics Market Analysis and Forecast, by Diagnostic Test Type, 2023-2031

• 7.1. Introduction and Definitions
• 7.2. Global Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
  • 7.2.1. Skin Biopsy
  • 7.2.2. Imaging Techniques
  • 7.2.3. Blood Test
  • 7.2.4. Electrocardiogram and Echocardiogram
  • 7.2.5. Pulmonary Function Tests
• 7.3. Global Scleroderma Diagnostics and Therapeutics Market Attractiveness, by Diagnostic Test Type

8. Global Scleroderma Diagnostics and Therapeutics Market Analysis and Forecast, by Region, 2023-2031

• 8.1. Key Findings
• 8.2. Global Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Region, 2023-2031
  • 8.2.1. North America
  • 8.2.2. Europe
  • 8.2.3. Asia Pacific
  • 8.2.4. Middle East & Africa
  • 8.2.5. Latin America
• 8.3. Global Scleroderma Diagnostics and Therapeutics Market Attractiveness, by Region

9. North America Scleroderma Diagnostics and Therapeutics Market Analysis and Forecast, 2023-2031

• 9.1. Key Findings
• 9.2. North America Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
• 9.3. North America Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
• 9.4. North America Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
• 9.5. North America Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Country, 2023-2031
  • 9.5.1. U.S. Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
  • 9.5.2. U.S. Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
  • 9.5.3. U.S. Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
  • 9.5.4. Canada Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
  • 9.5.5. Canada Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
  • 9.5.6. Canada Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
• 9.6. North America Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis

10. Europe Scleroderma Diagnostics and Therapeutics Market Analysis and Forecast, 2023-2031

• 10.1. Key Findings
• 10.2. Europe Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
• 10.3. Europe Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
• 10.4. Europe Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
• 10.5. Europe Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Country and Sub-region, 2023-2031
  • 10.5.1. Germany Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
  • 10.5.2. Germany Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
  • 10.5.3. Germany Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
  • 10.5.4. France Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
  • 10.5.5. France Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
  • 10.5.6. France Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
  • 10.5.7. U.K. Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
  • 10.5.8. U.K. Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
  • 10.5.9. U.K. Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
  • 10.5.10. Italy Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
  • 10.5.11. Italy. Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
  • 10.5.12. Italy Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
  • 10.5.13. Russia & CIS Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
  • 10.5.14. Russia & CIS Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
  • 10.5.15. Russia & CIS Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
  • 10.5.16. Rest of Europe Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
  • 10.5.17. Rest of Europe Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
  • 10.5.18. Rest of Europe Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
• 10.6. Europe Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis

11. Asia Pacific Scleroderma Diagnostics and Therapeutics Market Analysis and Forecast, 2023-2031

• 11.1. Key Findings
• 11.2. Asia Pacific Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class
• 11.3. Asia Pacific Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
• 11.4. Asia Pacific Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
• 11.5. Asia Pacific Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Country and Sub-region, 2023-2031
  • 11.5.1. China Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
  • 11.5.2. China Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
  • 11.5.3. China Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
  • 11.5.4. Japan Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
  • 11.5.5. Japan Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
  • 11.5.6. Japan Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
  • 11.5.7. India Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
  • 11.5.8. India Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
  • 11.5.9. India Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
  • 11.5.10. ASEAN Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
  • 11.5.11. ASEAN Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
  • 11.5.12. ASEAN Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
  • 11.5.13. Rest of Asia Pacific Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
  • 11.5.14. Rest of Asia Pacific Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
  • 11.5.15. Rest of Asia Pacific Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
• 11.6. Asia Pacific Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis

12. Latin America Scleroderma Diagnostics and Therapeutics Market Analysis and Forecast, 2023-2031

• 12.1. Key Findings
• 12.2. Latin America Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
• 12.3. Latin America Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
• 12.4. Latin America Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
• 12.5. Latin America Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Country and Sub-region, 2023-2031
  • 12.5.1. Brazil Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
  • 12.5.2. Brazil Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
  • 12.5.3. Brazil Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
  • 12.5.4. Mexico Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
  • 12.5.5. Mexico Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
  • 12.5.6. Mexico Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
  • 12.5.7. Rest of Latin America Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
  • 12.5.8. Rest of Latin America Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
  • 12.5.9. Rest of Latin America Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
• 12.6. Latin America Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis

13. Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Analysis and Forecast, 2023-2031

• 13.1. Key Findings
• 13.2. Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
• 13.3. Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
• 13.4. Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
• 13.5. Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Country and Sub-region, 2023-2031
  • 13.5.1. GCC Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
  • 13.5.2. GCC Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
  • 13.5.3. GCC Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
  • 13.5.4. South Africa Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
  • 13.5.5. South Africa Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
  • 13.5.6. South Africa Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
  • 13.5.7. Rest of Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
  • 13.5.8. Rest of Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
  • 13.5.9. Rest of Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
• 13.6. Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis

14. Competition Landscape

• 14.1. Global Scleroderma Diagnostics and Therapeutics Company Market Share Analysis, 2022
• 14.2. Company Profiles (Details - Overview, Financials, Recent Developments, and Strategy)
  • 14.2.1. Johnson & Johnson Services, Inc.
    • 14.2.1.1. Company Description
    • 14.2.1.2. Business Overview
    • 14.2.1.3. Financial Overview
    • 14.2.1.4. Strategic Overview
  • 14.2.2. Boehringer Ingelheim
    • 14.2.2.1. Company Description
    • 14.2.2.2. Business Overview
    • 14.2.2.3. Financial Overview
    • 14.2.2.4. Strategic Overview
  • 14.2.3. Bayer AG
    • 14.2.3.1. Company Description
    • 14.2.3.2. Business Overview
    • 14.2.3.3. Financial Overview
    • 14.2.3.4. Strategic Overview
  • 14.2.4. Cytori Therapeutics, Inc.
    • 14.2.4.1. Company Description
    • 14.2.4.2. Business Overview
    • 14.2.4.3. Financial Overview
    • 14.2.4.4. Strategic Overview
  • 14.2.5. Corbus Pharmaceuticals Holdings Inc.
    • 14.2.5.1. Company Description
    • 14.2.5.2. Business Overview
    • 14.2.5.3. Financial Overview
    • 14.2.5.4. Strategic Overview
  • 14.2.6. Cumberland Pharmaceuticals, Inc.
    • 14.2.6.1. Company Description
    • 14.2.6.2. Business Overview
    • 14.2.6.3. Financial Overview
    • 14.2.6.4. Strategic Overview
  • 14.2.7. Gilead Sciences, Inc.
    • 14.2.7.1. Company Description
    • 14.2.7.2. Business Overview
    • 14.2.7.3. Financial Overview
    • 14.2.7.4. Strategic Overview
  • 14.2.8. Sanofi S.A.
    • 14.2.8.1. Company Description
    • 14.2.8.2. Business Overview
    • 14.2.8.3. Financial Overview
    • 14.2.8.4. Strategic Overview
  • 14.2.9. Pfizer Inc.
    • 14.2.9.1. Company Description
    • 14.2.9.2. Business Overview
    • 14.2.9.3. Financial Overview
    • 14.2.9.4. Strategic Overview
  • 14.2.10. F. Hoffmann-La Roche AG
    • 14.2.10.1. Company Description
    • 14.2.10.2. Business Overview
    • 14.2.10.3. Financial Overview
    • 14.2.10.4. Strategic Overview
  • 14.2.11. Merck & Co., Inc.
    • 14.2.11.1. Company Description
    • 14.2.11.2. Business Overview
    • 14.2.11.3. Financial Overview
    • 14.2.11.4. Strategic Overview

15. Primary Research: Key Insights

16. Appendix